Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939765 | 0.92 | CYP2D6 (0.43) | CYP2D6MAPTLMNAMEN1KMT2A | |
| SCHEMBL9939525 | 0.87 | CYP2D6 (0.38) | CYP2D6MAPTRAPGEF3RAPGEF4MEN1 | |
| SCHEMBL9939647 | 0.87 | TP53 (0.44) | MAPTRAPGEF3LMNAMEN1NPC1 | |
| SCHEMBL9939492 | 0.87 | CYP2D6 (0.40) | CYP2D6MAPTRAPGEF3RAPGEF4MEN1 | |
| SCHEMBL9939562 | 0.86 | CYP2D6 (0.47) | CYP2D6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL9939551 | 0.86 | CYP2D6 (0.37) | CYP2D6RAPGEF3RAPGEF4MEN1RAB9A | |
| SCHEMBL9939556 | 0.84 | MAPT (0.48) | MAPTLMNAMEN1NPC1RAB9A | |
| SCHEMBL9939676 | 0.83 | RXFP1 (0.48) | MAPTLMNAMEN1KMT2ARXFP1 | |
| SCHEMBL15479558 | 0.81 | MAPT (0.46) | CYP2D6MAPTLMNAMEN1KMT2A | |
| SCHEMBL19362724 | 0.81 | CYP2D6 (0.48) | CYP2D6MAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2648710-B1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140051727-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012078869-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | CYP2D6 1332/4885MAPT 2707/4885RAPGEF3 244/4885 |
| US-20140051727-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | CYP2D6 1332/4885MAPT 2707/4885RAPGEF3 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.